A61K 31/4402
Only substituted in position 2
Official title: only substituted in position 2, e.g. pheniramine, bisacodyl
A61K31/4402 (Only substituted in position 2) appears on 696 US grants and 1,151 published applications in this corpus.
Search patents in A61K- Granted patents
- 696
- Published applications
- 1,151
- Assignees
- 628
- Inventors
- 2,502
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 18 | 0 |
| 1998 | 13 | 0 |
| 1999 | 13 | 0 |
| 2000 | 13 | 0 |
| 2001 | 17 | 4 |
| 2002 | 17 | 18 |
| 2003 | 8 | 20 |
| 2004 | 4 | 33 |
| 2005 | 11 | 25 |
| 2006 | 16 | 20 |
| 2007 | 10 | 25 |
| 2008 | 8 | 22 |
| 2009 | 9 | 33 |
| 2010 | 10 | 38 |
| 2011 | 12 | 32 |
| 2012 | 10 | 30 |
| 2013 | 23 | 57 |
| 2014 | 27 | 66 |
| 2015 | 41 | 84 |
| 2016 | 40 | 77 |
| 2017 | 52 | 77 |
| 2018 | 45 | 72 |
| 2019 | 54 | 67 |
| 2020 | 43 | 67 |
| 2021 | 45 | 61 |
| 2022 | 45 | 51 |
| 2023 | 26 | 52 |
| 2024 | 25 | 43 |
| 2025 | 25 | 47 |
| 2026 | 14 | 30 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies15 Sep 2026US 12,734,166 B2ChemoCentryx, Inc.
- Arylsulfonamides as orexin receptor agonists8 Sep 2026US 12,729,178 B2Research Triangle Institute
- Method of treating triple-negative breast cancer25 Aug 2026US 12,714,691 B2Dana-Farber Cancer Institute, Inc.
- Bacterial DNA gyrase inhibitors and methods of use thereof25 Aug 2026US 12,714,692 B2The Florida International University Board of Trustees
- Enteric bisacodyl softgel capsule11 Aug 2026US 12,702,647 B2R.P. Scherer Technologies, LLC
- Methods for treating gastrointestinal inflammatory diseases using alpha-ketoglutarate (akg) modulators1 Oct 2026US 2026/0294856 A1
- Pyridine-piperazine-based scaffolds as highly potent and selective neurolysin activators1 Oct 2026US 2026/0294897 A1Board of Regents of the University of Nebraska
- Benzalkonium chloride for use in treating conjunctivitis and/or covid-1924 Sep 2026US 2026/0283984 A1Bausch + Lomb Ireland Limited
- Modulators of sortilin activity24 Sep 2026US 2026/0285802 A1
- Methods for treating aortic valve stenosis with a hedgehog pathway inhibitor10 Sep 2026US 2026/0263396 A1The Trustees of Indiana University
Most cited
By later US patents
- Aerosol formulations containing propellant 134a and fluticasone propionate159US 5,658,549 AGlaxo Group Limited · 1997
- Methods and compositions for inhibiting cell proliferative disorders109US 5,789,427 ASugen, Inc. · 1998
- Canisters containing aerosol formulations containing P134a and fluticasone propionate107US 5,674,472 AGlaxo Group Limited · 1997
- Modified release formulations containing drug-ion exchange resin complexes103US 8,062,667 B2Tris Pharma, Inc. · 2011
- Modified release formulations containing drug-ion exchange resin complexes97US 8,202,537 B2Tris Pharma, Inc. · 2012